title: Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
abstract: The present case involves a 47-yr-old woman with Cushing's disease due to pituitary macroadenoma. The patient had suffered from hypertension and obesity for two yr. Her serum cortisol levels were moderately elevated throughout the observation period, and dexamethasone failed to suppress the cortisol secretion. Plasma ACTH levels were markedly high (>100 pg/ml) and did not respond to CRH provocation. Gel filtration analysis of the patient's plasma detected the existence of big ACTH molecules, which eluted with a peak of authentic 1-39 ACTH. Cranial magnetic resonance imaging (MRI) revealed a 3 cm pituitary tumor occupying the sellar region and right cavernous sinus with diffuse enhancement by gadolinium. The pituitary mass was removed by transsphenoidal surgery, and was pathologically identified as compatible to ACTH-producing pituitary adenoma by immunohistochemistry. RT-PCR analysis of total cellular RNA extracted from the resected adenoma revealed a relatively high expression level of dopamine D2 receptor (D2R) mRNA. Therefore, a long-acting D2R agonist, cabergoline (0.25 to 0.5 mg/week), was administered for the remnant adenoma, which gradually reduced ACTH levels in 90 days. In addition, cranial MRI exhibited shrinkage of the remnant pituitary mass after a 6-month treatment with cabergoline. This case demonstrates the efficacy of cabergoline to treat Cushing's disease caused by pituitary macroadenoma secreting aberrant ACTH molecules.
authors.affiliation: Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Miyoshi
authors.forename: F
authors.initials: F
authors.lastname: Otsuka
authors.forename: M
authors.initials: M
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Inagaki
authors.forename: J
authors.initials: J
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Ogura
authors.forename: I
authors.initials: I
authors.lastname: Date
authors.forename: K
authors.initials: K
authors.lastname: Hashimoto
authors.forename: H
authors.initials: H
authors.lastname: Makino
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy* / Q000209:etiology*; D010911:Pituitary Neoplasms / Q000150:complications* / Q000473:pathology; D017448:Receptors, Dopamine D2 / Q000032:analysis; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D017448:Receptors, Dopamine D2; D000324:Adrenocorticotropic Hormone; D000077465:Cabergoline